Description
Tirzepatide research peptide
Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors. It is a C20 fatty-diacid-acylated peptide with a long half-life and is a reference compound in incretin research.
Product details
| Compound | Tirzepatide |
|---|---|
| Class | Dual GIP / GLP-1 receptor agonist |
| Form | Peptide; Nasal Spray; Sublingual Tablets |
| Strength | 5mg; 10mg; 100mcg per spray/10ml/10mg; 200mcg per spray/10ml/20mg; 350mcg per tablet/30ct/10.5mg; 350mcg per tablet/60ct/21mg; 60mg |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What Tirzepatide research has examined
- Dual incretin agonism: combined GIP and GLP-1 receptor signalling.
- Clinical research: the SURPASS and SURMOUNT trial programmes.
- Comparative research: versus selective GLP-1 agonists such as semaglutide.
Research interest does not establish a proven effect in humans.
Regulatory status
Licensed medicines containing this active ingredient are prescription-only products made by authorised manufacturers. The material sold here is a research chemical, not a licensed medicine, and is not approved for any use in humans.
Storage and handling
Store lyophilised vials cold, dry and away from light. Reconstitute with a suitable sterile diluent under aseptic conditions and keep solutions refrigerated. See our peptide reconstitution guide.
Related research products
Tirzepatide + Semaglutide Blend · N-Acetyl Selank Nasal Spray · Gonadorelin Acetate Spray · All peptide sprays
References
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.